Document is current

Article History

Received: 6 October 2017

Accepted: 6 March 2018

First Online: 3 May 2018

Ethics approval and consent to participate

: This study involves secondary data analysis of de-identified data. There were no individual participants in this study.

: Not applicable.

: JAS has received research grants from Takeda and Savient Pharmaceuticals and consultant’s fees from Savient Pharmaceuticals, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon, Allergan Pharmaceuticals, WebMD, UBM LLC, Medscape, Fidia Pharmaceuticals, and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon Pharmaceuticals through a grant to DINORA, Inc., a 501(c)(3) entity. JAS is a member of the executive board of OMERACT, an organization that develops outcome measures in rheumatology and receives arm’s-length funding from 36 companies; is a member of the American College of Rheumatology’s (ACR’s) Annual Meeting Planning Committee (AMPC); is chair of the ACR Meet-the-Professor Workshop and Study Group Subcommittee; and is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. TRM declares receiving grant funding from Ardea Biosciences and Ironwood Pharmaceuticals. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.